Patient-Important Adverse Events of ß-blockers in Frail Older Adults after Acute Myocardial Infarction.

Zullo AR, Olean M, Berry SD, Lee Y, Tjia J, Steinman MA. Patient-Important Adverse Events of ß-blockers in Frail Older Adults after Acute Myocardial Infarction. The journals of gerontology. Series A, Biological sciences and medical sciences. 2019 Jul 12; 74(8):1277-1281.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: We evaluated the burden of adverse events caused by ß-blocker use after acute myocardial infarction (AMI) in frail, older nursing home (NH) residents. METHODS: This retrospective cohort study used national Medicare claims linked to Minimum Data Set assessments. The study population was individuals aged = 65 years who resided in a U.S. NH for = 30 days, had a hospitalized AMI between May 2007 and March 2010, and returned to the NH. Exposure was new use of ß-blockers versus nonuse post-AMI. Orthostasis, general hypotension, falls, dizziness, syncope, and breathlessness outcomes were measured over 90 days of follow-up. Odds ratios (ORs) with 95% confidence intervals (CIs) for outcomes were estimated using multinomial logistic regression models after 1:1 propensity score-matching of ß-blocker users to nonusers. RESULTS: Among the 10,992 NH propensity score-matched residents with an AMI, the mean age was 84 years and 70.9% were female. ß-blocker users were more likely than nonusers to be hospitalized for hypotension (OR = 1.20, 95% CI 1.03-1.39) or experience breathlessness (OR = 1.10, 95% CI 1.01-1.20) after AMI. With the exception of falls, other outcome estimates, though imprecise, were compatible with a potential elevated risk of orthostasis (OR = 1.14, 95% CI 0.96-1.35), syncope, (OR = 1.24, 95% CI 0.55-2.77), and dizziness (OR = 1.28, 95% CI 0.82-1.99) among ß-blocker users. CONCLUSIONS: Considered alongside prior evidence that ß-blockers may worsen functional outcomes in NH residents with poor baseline functional and cognitive status, our results suggest that providers should exercise caution when prescribing for these vulnerable groups, balancing the mortality benefit against the potential for causing adverse events.